NEW YORK–(BUSINESS WIRE)–As recent headlines ignite conversations about ketamine use across campuses, Mountainside Treatment Center is urging colleges and universities to ensure students have clear information about the dangers of ketamine and to make support available to the campus community. Ketamine was first synthesized in 1962 and approved by the U.S. FDA in 1970. It is primarily used as an anesthetic in medical settings but has gained attention for its off-label use in treating conditio
Author: sHq_LoGiNz
NEW YORK–(BUSINESS WIRE)–As recent headlines ignite conversations about ketamine use across campuses, Mountainside Treatment Center is urging colleges and universities to ensure students have clear information about the dangers of ketamine and to make support available to the campus community. Ketamine was first synthesized in 1962 and approved by the U.S. FDA in 1970. It is primarily used as an anesthetic in medical settings but has gained attention for its off-label use in treating conditio
DETROIT–(BUSINESS WIRE)–Ford Motor Company, JPMorganChase, the State of Michigan, Michigan Central and Newlab today announced the Michigan Launchpad for Industrial Innovation & Transformation (Michigan LIFT), a public-private initiative designed to strengthen manufacturers’ competitiveness and supply-chain resilience while accelerating the growth of innovative suppliers expanding production in Michigan. The platform translates manufacturing and supply-chain challenges identified by indust
DETROIT–(BUSINESS WIRE)–Ford Motor Company, JPMorganChase, the State of Michigan, Michigan Central and Newlab today announced the Michigan Launchpad for Industrial Innovation & Transformation (Michigan LIFT), a public-private initiative designed to strengthen manufacturers’ competitiveness and supply-chain resilience while accelerating the growth of innovative suppliers expanding production in Michigan. The platform translates manufacturing and supply-chain challenges identified by indust
BROOKLYN, N.Y.–(BUSINESS WIRE)–Destro AI, the company building the shared intelligence layer for warehouse robotics, today announced it has raised $8 million in seed funding co-led by Base10 Partners and Bonfire Ventures, with participation from CoFound Partners. The funding will accelerate deployment of Destro’s platform across enterprise warehouses and expand the company’s engineering and research teams. As an industry, warehouse robotics has never moved faster. Hardware has become dramatic
BROOKLYN, N.Y.–(BUSINESS WIRE)–Destro AI, the company building the shared intelligence layer for warehouse robotics, today announced it has raised $8 million in seed funding co-led by Base10 Partners and Bonfire Ventures, with participation from CoFound Partners. The funding will accelerate deployment of Destro’s platform across enterprise warehouses and expand the company’s engineering and research teams. As an industry, warehouse robotics has never moved faster. Hardware has become dramatic
HARRISBURG, Pa.–(BUSINESS WIRE)–MITER Foundation, the charitable arm of MITER Brands, a family of leading window and door brands, recently celebrated two years of partnership with the American Foundation for Suicide Prevention (AFSP). The milestone coincides with Suicide Prevention Month, highlighting the continued importance of both organizations’ work to support suicide prevention efforts.Since the partnership’s inception in 2024, MITER Foundation and the AFSP have collaborated on various ef
HARRISBURG, Pa.–(BUSINESS WIRE)–MITER Foundation, the charitable arm of MITER Brands, a family of leading window and door brands, recently celebrated two years of partnership with the American Foundation for Suicide Prevention (AFSP). The milestone coincides with Suicide Prevention Month, highlighting the continued importance of both organizations’ work to support suicide prevention efforts.Since the partnership’s inception in 2024, MITER Foundation and the AFSP have collaborated on various ef
SAN DIEGO–(BUSINESS WIRE)–Vividion announces publication of first peer-reviewed clinical data from Phase 1 study of VVD-214, investigational oral inhibitor of WRN.
SAN DIEGO–(BUSINESS WIRE)–Vividion announces publication of first peer-reviewed clinical data from Phase 1 study of VVD-214, investigational oral inhibitor of WRN.